Sign In
Buy ASMB
$25.55
+0.330 (+1.31%)
At Close: Jul 24, 2026
Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
12:00pm, Wednesday, 22'nd Jun 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics
7 Penny Stocks That Could Triple in 2022
07:00am, Wednesday, 22'nd Jun 2022
Some stocks currently trading in penny stock territory have unique advantages that makes it worthwhile to overlook the inherent risk involved in investing in these stocks. The post 7 Penny Stocks That
Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022
12:00pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics t
SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics tar
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics t
Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
08:05pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics ta
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09:00pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatit
Assembly Biosciences GAAP EPS of -$3.00 misses by $0.90, revenue of $6.25M beats by $0.09M
11:06pm, Thursday, 10'th Mar 2022 Seeking Alpha
Assembly Biosciences press release (NASDAQ:ASMB): FY GAAP EPS of -$3.00 misses by $0.90.Revenue of $6.25M (-92.1% Y/Y) beats by $0.09M.
Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights
09:05pm, Thursday, 10'th Mar 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.
Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference
01:00pm, Wednesday, 09'th Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, AO, MD, chief executive officer and president, will participate in a virtual fireside chat during the SVB Leerink 11 th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 p.m. ET.
Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference
08:00am, Wednesday, 09'th Feb 2022
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:00pm, Friday, 07'th Jan 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatiti
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
01:00pm, Thursday, 06'th Jan 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatiti
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
08:00am, Thursday, 06'th Jan 2022
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)
03:00pm, Tuesday, 07'th Dec 2021 Zacks Investment Research
Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
